Ignacio
Matos García
Consultor Médico
Fondazione IRCCS Istituto Nazionale dei Tumori
Milán, ItaliaPublications in collaboration with researchers from Fondazione IRCCS Istituto Nazionale dei Tumori (3)
2022
-
Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: [ESMO Open Volume 7, Issue 2, April 2022, 100447] (ESMO Open (2022) 7(2), (S2059702922000631), (10.1016/j.esmoop.2022.100447))
ESMO Open
-
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors
ESMO Open, Vol. 7, Núm. 2
2020
-
Atypical patterns of response and progression in the era of immunotherapy combinations
Future Oncology, Vol. 16, Núm. 23, pp. 1707-1713